Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Allakos reports Q3 EPS (86c), consensus (82c) » 08:11
11/09/20
11/09
08:11
11/09/20
08:11
ALLK

Allakos

$99.46 /

-0.29 (-0.29%)

Allakos ended the third…

Allakos ended the third quarter of 2020 with $419.8 million in cash, cash equivalents and marketable securities, which does not include the $271.7 million of net proceeds received from the Company's follow-on public offering in November 2020.

ShowHide Related Items >><<
ALLK Allakos
$99.46 /

-0.29 (-0.29%)

ALLK Allakos
$99.46 /

-0.29 (-0.29%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
12/20/19 William Blair
Allakos remains a core midcap holding, says William Blair
ALLK Allakos
$99.46 /

-0.29 (-0.29%)

  • 29
    Oct
  • 13
    May
ALLK Allakos
$99.46 /

-0.29 (-0.29%)

Over a month ago
Syndicate
Allakos 3.05M share Secondary priced at $82.00 » 20:25
10/28/20
10/28
20:25
10/28/20
20:25
ALLK

Allakos

$84.04 /

-9.58 (-10.23%)

The deal priced below the…

The deal priced below the last closing price of $84.04. Jefferies, BofA and SVB Leerink are acting as joint book running managers for the offering.

ShowHide Related Items >><<
ALLK Allakos
$84.04 /

-9.58 (-10.23%)

ALLK Allakos
$84.04 /

-9.58 (-10.23%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
12/20/19 William Blair
Allakos remains a core midcap holding, says William Blair
ALLK Allakos
$84.04 /

-9.58 (-10.23%)

  • 29
    Oct
  • 13
    May
ALLK Allakos
$84.04 /

-9.58 (-10.23%)

Earnings
Allakos sees Q3 net loss of ($50M) to ($40M) vs. ($21.7M) last year » 20:01
10/27/20
10/27
20:01
10/27/20
20:01
ALLK

Allakos

$93.62 /

+2.57 (+2.82%)

Allakos estimates that…

Allakos estimates that cash, cash equivalents and investments in marketable securities will be $419.8M as of September 30, 2020.

ShowHide Related Items >><<
ALLK Allakos
$93.62 /

+2.57 (+2.82%)

ALLK Allakos
$93.62 /

+2.57 (+2.82%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
12/20/19 William Blair
Allakos remains a core midcap holding, says William Blair
ALLK Allakos
$93.62 /

+2.57 (+2.82%)

  • 29
    Oct
  • 13
    May
ALLK Allakos
$93.62 /

+2.57 (+2.82%)

Syndicate
Allakos files to sell$250M in common stock » 16:09
10/27/20
10/27
16:09
10/27/20
16:09
ALLK

Allakos

$36.00 /

+18 (+6.00%)

Jefferies, BofA…

Jefferies, BofA Securities and SVB Leerink are acting as joint book-running managers for the offering. LifeSci Capital LLC and William Blair are acting as co-managers for the offering.

ShowHide Related Items >><<
ALLK Allakos
$36.00 /

+18 (+6.00%)

ALLK Allakos
$36.00 /

+18 (+6.00%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
12/20/19 William Blair
Allakos remains a core midcap holding, says William Blair
ALLK Allakos
$36.00 /

+18 (+6.00%)

  • 13
    May
  • 13
    May
ALLK Allakos
$36.00 /

+18 (+6.00%)

Hot Stocks
Allakos reports results from prospective prevalence study » 07:25
10/26/20
10/26
07:25
10/26/20
07:25
ALLK

Allakos

$89.90 /

+3.39 (+3.92%)

Allakos reported results…

Allakos reported results from a prospective study examining the rates of elevated eosinophil and mast cell levels in patients with chronic unexplained gastrointestinal symptoms or functional gastrointestinal disorders such as irritable bowel syndrome and functional dyspepsia. The results suggest that eosinophilic gastritis and/or eosinophilic duodenitis are significantly underdiagnosed. This prospective, multi-center study assessed eosinophil and mast cell levels in biopsies obtained from patients with active, chronic unexplained gastrointestinal symptoms or FGIDs. Inclusion in the study required patients to have greater than or equal to6-month history of abdominal pain, abdominal cramping, nausea, vomiting, diarrhea, bloating and/or early satiety without identifiable cause and unresponsive to pharmacologic or dietary intervention, or a diagnosis of IBS or FD. Gastric and duodenal biopsies were performed in patients who had an average weekly single symptom severity score greater than or equal to3 for abdominal pain, abdominal cramping, nausea, vomiting, diarrhea, bloating or early satiety and a total symptom severity score greater than or equal to10 as assessed by the patient reported outcome questionnaire used in the Company's Phase 2 and Phase 3 EG and/or EoD studies. The primary endpoints were: The proportion of symptomatic patients that underwent biopsy and met the histologic criteria for EG and/or EoD. The proportion of symptomatic patients that underwent biopsy with greater than or equal to30 mast cells/HPF in five gastric HPFs and/or greater than or equal to30 mast cells/HPF in three duodenal HPFs and less than30 eosinophils/HPF, referred to as MGID. 73% of patients screened met the symptom severity criteria and underwent endoscopy with biopsy. Of the patients biopsied, 45% met the histologic criteria for EG and/or EoD, representing 33%. In addition, 50% of patients biopsied had greater than or equal to30 mast cells/HPF and less than30 eosinophils/HPF.

ShowHide Related Items >><<
ALLK Allakos
$89.90 /

+3.39 (+3.92%)

ALLK Allakos
$89.90 /

+3.39 (+3.92%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
12/20/19 William Blair
Allakos remains a core midcap holding, says William Blair
ALLK Allakos
$89.90 /

+3.39 (+3.92%)

  • 13
    May
ALLK Allakos
$89.90 /

+3.39 (+3.92%)

Hot Stocks
Allakos announces results from Phase 1 study of lirentelimab » 07:22
10/26/20
10/26
07:22
10/26/20
07:22
ALLK

Allakos

$89.90 /

+3.39 (+3.92%)

Allakos announced results…

Allakos announced results from a Phase 1 Study of subcutaneously administered lirentelimab in healthy volunteers. Based on these results, Allakos intends to investigate monthly dosing of the subcutaneous formulation of lirentelimab in patients with eosinophilic gastritis, eosinophilic duodenitis, eosinophilic esophagitis and other diseases. The randomized, double-blind, placebo-controlled, single dose, dose ranging Phase 1 Study was designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous lirentelimab in healthy volunteers over 85 days. Subjects enrolled in subcutaneously administered cohorts received a single SC dose of one of the following: 0.3, 1.0, 3.0, 5.0 mg/kg of lirentelimab, a 2 mL SC dose containing 300 mg of lirentelimab, or placebo. Bioavailability of SC lirentelimab was determined by comparing SC cohorts to cohorts that received intravenously administered lirentelimab. Bioavailability of SC lirentelimab was 63 percent. Subcutaneously administered lirentelimab resulted in extended eosinophil suppression at all dose levels tested. At dose levels of 3.0 and 5.0 mg/kg and with the fixed dose of 300 mg, SC lirentelimab resulted in eosinophil suppression in all subjects through Day 85. Subcutaneously administered lirentelimab was well tolerated. Across all SC and IV lirentelimab cohorts there were no serious adverse events, no injection site reactions, no injection reactions and no infusion-related reactions. One subject receiving placebo reported an injection reaction.

ShowHide Related Items >><<
ALLK Allakos
$89.90 /

+3.39 (+3.92%)

ALLK Allakos
$89.90 /

+3.39 (+3.92%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
12/20/19 William Blair
Allakos remains a core midcap holding, says William Blair
ALLK Allakos
$89.90 /

+3.39 (+3.92%)

  • 13
    May
ALLK Allakos
$89.90 /

+3.39 (+3.92%)

Hot Stocks
Allakos study shows clinically meaningful,statistically significant benefits » 17:02
10/21/20
10/21
17:02
10/21/20
17:02
ALLK

Allakos

$79.77 /

-0.96 (-1.19%)

Allakos announced the…

Allakos announced the publication of results from the multicenter, randomized, double-blind, placebo-controlled Phase 2 study of lirentelimab, AK002, in patients with eosinophilic gastritis and/or eosinophilic duodenitis, ENIGMA, in the New England Journal of Medicine. All AK002 dose arms showed clinically meaningful and statistically significant benefits compared to placebo on all prespecified primary and secondary endpoints, including gastrointestinal tissue eosinophil counts and patient-reported disease symptoms.

ShowHide Related Items >><<
ALLK Allakos
$79.77 /

-0.96 (-1.19%)

ALLK Allakos
$79.77 /

-0.96 (-1.19%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
12/20/19 William Blair
Allakos remains a core midcap holding, says William Blair
ALLK Allakos
$79.77 /

-0.96 (-1.19%)

  • 13
    May
ALLK Allakos
$79.77 /

-0.96 (-1.19%)

Over a quarter ago
Earnings
Allakos reports Q2 EPS (80c), consensus (61c) » 08:06
08/10/20
08/10
08:06
08/10/20
08:06
ALLK

Allakos

$84.91 /

+2.15 (+2.60%)

Patient enrollment was…

Patient enrollment was initiated in a randomized, double-blind, placebo-controlled Phase 3 study of AK002 in patients with eosinophilic gastritis and/or eosinophilic duodenitis. Topline data are expected in the second half of 2021. Patient enrollment was initiated in a randomized, double-blind, placebo-controlled Phase 2/3 study of AK002 in patients with eosinophilic esophagitis. Topline data are expected in the second half of 2021. The Phase 1 safety, tolerability and pharmacokinetics study of the subcutaneous formulation of AK002 is fully enrolled. Results are expected in the second half of 2020. The non-interventional study examining the prevalence of EG, EoD, and mast cell gastrointestinal disease in patients with chronic functional gastrointestinal disease is fully enrolled. Results are expected in the second half of 2020. Announced positive clinical safety and efficacy results from a six-month, open-label Phase 1 study of AK002 in patients with MGID in March 2020. Announced positive interim safety and efficacy results from the open-label, long-term extension component of the ENIGMA study with AK002 in patients with EG and/or EoD. The results were accepted for oral presentation and presented virtually at the Digestive Disease Week Annual Meeting in May 2020. The nonproprietary name of AK002 was changed from antolimab to lirentelimab as a result of trademark issues identified outside of the United States. Lirentelimab has been adopted by the United States Adopted Names Council and World Health Organization International Nonproprietary Name Program.

ShowHide Related Items >><<
ALLK Allakos
$84.91 /

+2.15 (+2.60%)

ALLK Allakos
$84.91 /

+2.15 (+2.60%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
12/20/19 William Blair
Allakos remains a core midcap holding, says William Blair
ALLK Allakos
$84.91 /

+2.15 (+2.60%)

  • 13
    May
ALLK Allakos
$84.91 /

+2.15 (+2.60%)

ALLK Allakos
$84.91 /

+2.15 (+2.60%)

Conference/Events
William Blair to hold a virtual conference » 09:55
08/04/20
08/04
09:55
08/04/20
09:55
RCUS

Arcus Biosciences

$20.42 /

-0.61 (-2.90%)

, AGEN

Agenus

$3.20 /

-0.055 (-1.69%)

, EXEL

Exelixis

$23.06 /

-0.64 (-2.70%)

, CALA

Calithera Biosciences

$4.85 /

-0.02 (-0.41%)

, RGEN

Repligen

$155.50 /

-3.02 (-1.91%)

, PIRS

Pieris Pharmaceuticals

$2.68 /

-0.025 (-0.92%)

, CYAD

Celyad

$9.87 /

+ (+0.00%)

, FATE

Fate Therapeutics

$32.33 /

-0.92 (-2.77%)

, CLLS

Cellectis

$17.44 /

+ (+0.00%)

, AUTL

Autolus Therapeutics

$13.92 /

+ (+0.00%)

, GRTS

Gritstone Oncology

$3.35 /

+0.03 (+0.90%)

, ADPT

Adaptive Biotechnologies

$39.49 /

+0.12 (+0.30%)

, TBIO

Translate Bio

$15.60 /

-0.14 (-0.89%)

, EBS

Emergent BioSolutions

$122.01 /

+4.045 (+3.43%)

, ITCI

Intra-Cellular

$20.77 /

-0.15 (-0.72%)

, KRTX

Karuna Therapeutics

$86.82 /

-0.68 (-0.78%)

, ASMB

Assembly Biosciences

$23.15 /

+0.03 (+0.13%)

, NCNA

NuCana

$6.55 /

+0.4 (+6.50%)

, AXSM

Axsome Therapeutics

$74.50 /

-1.82 (-2.38%)

, OVID

Ovid Therapeutics

$6.61 /

-0.16 (-2.36%)

, ALLK

Allakos

$78.92 /

-0.57 (-0.72%)

, NBIX

Neurocrine

$124.09 /

+0.92 (+0.75%)

, XENE

Xenon Pharmaceuticals

$11.51 /

+ (+0.00%)

, CRSP

Crispr Therapeutics

$91.70 /

-0.85 (-0.92%)

, BEAM

Beam Therapeutics

$19.00 /

+0.03 (+0.16%)

, GBT

Global Blood Therapeutics

$68.59 /

-2.08 (-2.94%)

, IONS

Ionis Pharmaceuticals

$58.45 /

-0.78 (-1.32%)

, RTRX

Retrophin

$20.19 /

+ (+0.00%)

Biotech Focus Virtual…

Biotech Focus Virtual Conference 2020 will be held on August 4-6 beginning at 10 am on August 4. Webcast Link

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RTRX Retrophin
$20.19 /

+ (+0.00%)

RGEN Repligen
$155.50 /

-3.02 (-1.91%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CYAD Celyad
$9.87 /

+ (+0.00%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

AGEN Agenus
$3.20 /

-0.055 (-1.69%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
AGEN Agenus
$3.20 /

-0.055 (-1.69%)

01/09/20 B. Riley Securities
Arbutus Biopharma price target raised to $6 from $3 at B. Riley FBR
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 B. Riley Securities
Agenus resumed with a Buy at B. Riley FBR
11/19/19 B. Riley Securities
Agenus resumed with a Buy at B. Riley FBR
EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

05/11/20 Citi
Calithera Biosciences price target raised to $10 from $7 at Citi
05/08/20 H.C. Wainwright
Calithera Biosciences price target raised to $9.50 from $7 at H.C. Wainwright
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Jefferies
Jefferies starts Calithera at Buy ahead of three data catalysts
RGEN Repligen
$155.50 /

-3.02 (-1.91%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
CYAD Celyad
$9.87 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
CLLS Cellectis
$17.44 /

+ (+0.00%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

07/14/20 BTIG
Gritstone Oncology price target lowered to $17 from $31 at BTIG
ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

07/17/20 Cantor Fitzgerald
Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
NCNA NuCana
$6.55 /

+0.4 (+6.50%)

07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
07/23/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
01/27/20 William Blair
NuCana undervalued as first patients dosed in Phase 3 study, says William Blair
AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 Truist
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
06/18/20 Cantor Fitzgerald
Ovid Therapeutics price target raised to $13 from $7 at Cantor Fitzgerald
05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
ALLK Allakos
$78.92 /

-0.57 (-0.72%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
12/20/19 William Blair
Allakos remains a core midcap holding, says William Blair
NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

08/04/20 Canaccord
Neurocrine price target raised to $145 from $134 at Canaccord
08/04/20 SVB Leerink
Neurocrine price target raised to $120 from $105 at SVB Leerink
08/04/20 Piper Sandler
Neurocrine price target raised to $145 from $141 at Piper Sandler
08/04/20 H.C. Wainwright
Neurocrine price target raised to $140 from $131 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
07/20/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
06/01/20
Fly Intel: Top five analyst initiations
CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
07/28/20 Oppenheimer
Crispr Therapeutics price target raised to $105 from $89 at Oppenheimer
07/28/20 Barclays
Crispr Therapeutics price target raised to $102 from $65 at Barclays
BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
03/02/20 JPMorgan
Beam Therapeutics initiated with an Overweight at JPMorgan
03/02/20 Wedbush
Beam Therapeutics initiated with an Outperform at Wedbush
03/02/20 Jefferies
Beam Therapeutics initiated with a Buy at Jefferies
GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/05/20 Citi
Ionis Pharmaceuticals price target raised to $80 from $71 at Citi
05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
RTRX Retrophin
$20.19 /

+ (+0.00%)

07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
08/23/19 BMO Capital
Retrophin price target lowered to $33 from $38 at BMO Capital
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RTRX Retrophin
$20.19 /

+ (+0.00%)

RGEN Repligen
$155.50 /

-3.02 (-1.91%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

AGEN Agenus
$3.20 /

-0.055 (-1.69%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

  • 16
    Jul
  • 01
    Jul
  • 26
    Jun
  • 09
    Jun
  • 09
    Jun
  • 29
    May
  • 13
    May
  • 16
    Apr
  • 06
    Feb
  • 23
    Jan
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 08
    Jan
  • 19
    Dec
  • 12
    Dec
  • 21
    Nov
  • 21
    Nov
  • 04
    Oct
  • 18
    Sep
  • 12
    Sep
  • 12
    Sep
  • 07
    Aug
RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

Conference/Events
William Blair to hold a virtual conference » 08:49
08/04/20
08/04
08:49
08/04/20
08:49
RCUS

Arcus Biosciences

$21.03 /

+1.34 (+6.81%)

, AGEN

Agenus

$3.25 /

+0.205 (+6.73%)

, EXEL

Exelixis

$23.70 /

+0.64 (+2.78%)

, CALA

Calithera Biosciences

$4.87 /

+0.15 (+3.18%)

, RGEN

Repligen

$158.52 /

+7.46 (+4.94%)

, PIRS

Pieris Pharmaceuticals

$2.71 /

+0.135 (+5.25%)

, CYAD

Celyad

$9.87 /

+ (+0.00%)

, FATE

Fate Therapeutics

$33.25 /

+2 (+6.40%)

, CLLS

Cellectis

$17.44 /

+1.77 (+11.30%)

, AUTL

Autolus Therapeutics

$13.92 /

+0.72 (+5.45%)

, GRTS

Gritstone Oncology

$3.32 /

+0.115 (+3.59%)

, ADPT

Adaptive Biotechnologies

$39.37 /

+1.99 (+5.32%)

, TBIO

Translate Bio

$15.74 /

+0.56 (+3.69%)

, EBS

Emergent BioSolutions

$117.97 /

+6.755 (+6.07%)

, ITCI

Intra-Cellular

$20.92 /

+1.11 (+5.60%)

, KRTX

Karuna Therapeutics

$87.50 /

+5.89 (+7.22%)

, ASMB

Assembly Biosciences

$23.12 /

+0.9 (+4.05%)

, NCNA

NuCana

$6.15 /

+0.65 (+11.82%)

, AXSM

Axsome Therapeutics

$76.32 /

+4.97 (+6.97%)

, OVID

Ovid Therapeutics

$6.77 /

+0.32 (+4.96%)

, ALLK

Allakos

$79.49 /

+4.36 (+5.80%)

, NBIX

Neurocrine

$123.17 /

+2.8 (+2.33%)

, XENE

Xenon Pharmaceuticals

$11.51 /

+0.55 (+5.02%)

, CRSP

Crispr Therapeutics

$92.55 /

+7.15 (+8.37%)

, BEAM

Beam Therapeutics

$18.97 /

-0.31 (-1.61%)

, GBT

Global Blood Therapeutics

$70.67 /

+3.24 (+4.80%)

, IONS

Ionis Pharmaceuticals

$59.23 /

+1.7 (+2.95%)

, RTRX

Retrophin

$20.19 /

+0.385 (+1.94%)

Biotech Focus Virtual…

Biotech Focus Virtual Conference 2020 will be held on August 4-6 beginning at 10 am on August 4. Webcast Link

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

RGEN Repligen
$158.52 /

+7.46 (+4.94%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CYAD Celyad
$9.87 /

+ (+0.00%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

AGEN Agenus
$3.25 /

+0.205 (+6.73%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
AGEN Agenus
$3.25 /

+0.205 (+6.73%)

01/09/20 B. Riley Securities
Arbutus Biopharma price target raised to $6 from $3 at B. Riley FBR
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 B. Riley Securities
Agenus resumed with a Buy at B. Riley FBR
11/19/19 B. Riley Securities
Agenus resumed with a Buy at B. Riley FBR
EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

05/11/20 Citi
Calithera Biosciences price target raised to $10 from $7 at Citi
05/08/20 H.C. Wainwright
Calithera Biosciences price target raised to $9.50 from $7 at H.C. Wainwright
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Jefferies
Jefferies starts Calithera at Buy ahead of three data catalysts
RGEN Repligen
$158.52 /

+7.46 (+4.94%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
CYAD Celyad
$9.87 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

07/14/20 BTIG
Gritstone Oncology price target lowered to $17 from $31 at BTIG
ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

07/17/20 Cantor Fitzgerald
Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
NCNA NuCana
$6.15 /

+0.65 (+11.82%)

07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
07/23/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
01/27/20 William Blair
NuCana undervalued as first patients dosed in Phase 3 study, says William Blair
AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 Truist
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
06/18/20 Cantor Fitzgerald
Ovid Therapeutics price target raised to $13 from $7 at Cantor Fitzgerald
05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
ALLK Allakos
$79.49 /

+4.36 (+5.80%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
12/20/19 William Blair
Allakos remains a core midcap holding, says William Blair
NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

08/04/20 Canaccord
Neurocrine price target raised to $145 from $134 at Canaccord
08/04/20 SVB Leerink
Neurocrine price target raised to $120 from $105 at SVB Leerink
08/04/20 Piper Sandler
Neurocrine price target raised to $145 from $141 at Piper Sandler
08/04/20 H.C. Wainwright
Neurocrine price target raised to $140 from $131 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
07/20/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
06/01/20
Fly Intel: Top five analyst initiations
CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
07/28/20 Oppenheimer
Crispr Therapeutics price target raised to $105 from $89 at Oppenheimer
07/28/20 Barclays
Crispr Therapeutics price target raised to $102 from $65 at Barclays
BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
03/02/20 JPMorgan
Beam Therapeutics initiated with an Overweight at JPMorgan
03/02/20 Wedbush
Beam Therapeutics initiated with an Outperform at Wedbush
03/02/20 Jefferies
Beam Therapeutics initiated with a Buy at Jefferies
GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/05/20 Citi
Ionis Pharmaceuticals price target raised to $80 from $71 at Citi
05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
08/23/19 BMO Capital
Retrophin price target lowered to $33 from $38 at BMO Capital
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

RGEN Repligen
$158.52 /

+7.46 (+4.94%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

AGEN Agenus
$3.25 /

+0.205 (+6.73%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

  • 16
    Jul
  • 01
    Jul
  • 26
    Jun
  • 09
    Jun
  • 09
    Jun
  • 29
    May
  • 13
    May
  • 16
    Apr
  • 06
    Feb
  • 23
    Jan
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 08
    Jan
  • 19
    Dec
  • 12
    Dec
  • 21
    Nov
  • 21
    Nov
  • 04
    Oct
  • 18
    Sep
  • 12
    Sep
  • 12
    Sep
  • 07
    Aug
RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.